CN112424347A - 治疗酸性鞘磷脂酶缺乏症的药物组合物 - Google Patents

治疗酸性鞘磷脂酶缺乏症的药物组合物 Download PDF

Info

Publication number
CN112424347A
CN112424347A CN201980048133.7A CN201980048133A CN112424347A CN 112424347 A CN112424347 A CN 112424347A CN 201980048133 A CN201980048133 A CN 201980048133A CN 112424347 A CN112424347 A CN 112424347A
Authority
CN
China
Prior art keywords
leu
pro
composition
ala
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980048133.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·杨
C·布瑟
B·佩雷斯-拉米雷斯
G·特里韦勒
S·本杰瓦尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New Co
Genzyme Corp
Original Assignee
New Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Co filed Critical New Co
Publication of CN112424347A publication Critical patent/CN112424347A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/04Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201980048133.7A 2018-05-25 2019-05-24 治疗酸性鞘磷脂酶缺乏症的药物组合物 Pending CN112424347A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862676525P 2018-05-25 2018-05-25
US62/676,525 2018-05-25
PCT/US2019/033983 WO2019227029A1 (en) 2018-05-25 2019-05-24 Pharmaceutical compositions for treating acid sphingomyelinase deficiency

Publications (1)

Publication Number Publication Date
CN112424347A true CN112424347A (zh) 2021-02-26

Family

ID=66912954

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980048133.7A Pending CN112424347A (zh) 2018-05-25 2019-05-24 治疗酸性鞘磷脂酶缺乏症的药物组合物

Country Status (15)

Country Link
US (1) US20210145941A1 (https=)
EP (1) EP3802805A1 (https=)
JP (2) JP7497300B2 (https=)
KR (1) KR102852946B1 (https=)
CN (1) CN112424347A (https=)
AU (2) AU2019275109C1 (https=)
BR (1) BR112020023829A2 (https=)
CA (1) CA3101688A1 (https=)
CO (1) CO2020014399A2 (https=)
IL (1) IL278964A (https=)
MX (2) MX2020012700A (https=)
PY (1) PY1939780A (https=)
SG (1) SG11202011488WA (https=)
UY (1) UY38238A (https=)
WO (1) WO2019227029A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024506860A (ja) * 2021-02-01 2024-02-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ニーマンピック病a型を治療するための組成物及び方法
TW202403043A (zh) 2022-03-18 2024-01-16 美商健臻公司 重組人類酸性鞘磷脂酶醫藥組合物及方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101431960A (zh) * 2006-01-20 2009-05-13 建新公司 用于溶酶体贮积症的脑室内酶输注系统
WO2010148337A1 (en) * 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
CN103260637A (zh) * 2010-06-25 2013-08-21 夏尔人类遗传性治疗公司 乙酰肝素n-硫酸酯酶cns递送的方法和组合物
WO2017149199A1 (en) * 2016-02-29 2017-09-08 Faron Pharmaceuticals Oy A lyophilised pharmaceutical formulation and its use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
ES2351786T3 (es) * 2001-11-13 2011-02-10 Genentech, Inc. Formulaciones con ligando apo2/trail y usos de las mismas.
WO2004112826A1 (en) 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
JP2007514661A (ja) * 2003-11-25 2007-06-07 マウント シナイ スクール オブ メディスン オブ ニューヨーク ユニバーシティー ニーマンピック病のシャペロンに基づく治療方法
HRP20120994T1 (hr) 2006-02-07 2012-12-31 Shire Human Genetic Therapies, Inc. Stabilizirana smjesa glukocerebrozidaze
MX2008011842A (es) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Procedimientos y composiciones para el tratamiento de insuficiencia cardiaca diastolica.
CN102943106A (zh) * 2006-03-13 2013-02-27 珀金埃尔默健康科学股份有限公司 用于质谱法检测的底物和内标
SI3998078T1 (sl) 2009-08-28 2026-02-27 Genzyme Corporation Encimsko nadomestno zdravljenje z naraščajočim odmerkom za zdravljenje pomanjkanja kisle sfingomielinaze
WO2012134240A2 (ko) * 2011-03-31 2012-10-04 (주)메디톡스 보툴리눔 독소의 동결건조제제
JP6480154B2 (ja) 2014-11-06 2019-03-06 持田製薬株式会社 エタネルセプトの凍結乾燥製剤
KR20250025051A (ko) * 2017-08-24 2025-02-20 사노피 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101431960A (zh) * 2006-01-20 2009-05-13 建新公司 用于溶酶体贮积症的脑室内酶输注系统
WO2010148337A1 (en) * 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
CN103260637A (zh) * 2010-06-25 2013-08-21 夏尔人类遗传性治疗公司 乙酰肝素n-硫酸酯酶cns递送的方法和组合物
WO2017149199A1 (en) * 2016-02-29 2017-09-08 Faron Pharmaceuticals Oy A lyophilised pharmaceutical formulation and its use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAMES M. MURRAY等: ""Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency: The utility of animal models of disease in the toxicological evaluation of potential therapeutics"", 《MOLECULAR GENETICS AND METABOLISM》, vol. 114, no. 02, pages 217 *

Also Published As

Publication number Publication date
EP3802805A1 (en) 2021-04-14
UY38238A (es) 2019-12-31
WO2019227029A1 (en) 2019-11-28
PY1939780A (es) 2019-12-04
JP2021525083A (ja) 2021-09-24
IL278964A (en) 2021-01-31
AU2025205577A1 (en) 2025-08-07
US20210145941A1 (en) 2021-05-20
MX2025002733A (es) 2025-04-02
JP7497300B2 (ja) 2024-06-10
JP7832245B2 (ja) 2026-03-17
CO2020014399A2 (es) 2020-12-10
CA3101688A1 (en) 2019-11-28
AU2019275109C1 (en) 2025-11-13
MX2020012700A (es) 2021-04-28
BR112020023829A2 (pt) 2021-05-11
JP2024069459A (ja) 2024-05-21
AU2019275109B2 (en) 2025-04-17
AU2019275109A1 (en) 2021-01-21
SG11202011488WA (en) 2020-12-30
KR20210015903A (ko) 2021-02-10
KR102852946B1 (ko) 2025-09-02

Similar Documents

Publication Publication Date Title
KR101772674B1 (ko) 동결건조된 재조합 vwf 제제
JP7832245B2 (ja) 酸性スフィンゴミエリナーゼ欠損症を治療するための医薬組成物
WO2015101182A1 (zh) 纽兰格林制剂的配方
KR20160146736A (ko) Hgf의 동결건조 제제
EP3125923B1 (en) Lyophilized pharmaceutical composition of fc-peptide fusion protein
EP3423042B1 (en) A lyophilised pharmaceutical formulation and its use
EP1855661B1 (en) Formulation for aviptadil
RU2826120C2 (ru) Фармацевтические композиции для лечения недостаточности кислой сфингомиелиназы
CN119278029A (zh) 包含含有α-半乳糖苷酶A的融合蛋白的冻干制剂
CN108210890A (zh) 重组人胰高血糖素样肽-1类似物融合蛋白的新型稳定制剂
CN111195349B (zh) 一种代谢调节融合蛋白的冻干粉制剂
TW202525329A (zh) 含有α-半乳糖苷酶A融合蛋白的新穎冷凍乾燥製劑
HK40077155A (en) A lyophilised pharmaceutical formulation and its use
EA044682B1 (ru) Фармацевтическая композиция, содержащая ромиплостим
HK1122214A (en) Formulation for aviptadil
NZ751555B2 (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency
HK1220403B (en) C1-inh compositions for use in the prevention and treatment of hereditary angioedema (hae).
HK1220403A1 (en) C1-inh compositions for use in the prevention and treatment of hereditary angioedema (hae).

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination